Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The peptide demonstrates specificity in gene expression modulation, particularly affecting Egr, Nos, Srf, Vegr, Akt1, Plc, and Kras genes, which collectively regulate cell growth, proliferation, survival, and vascular development
Perceived Versatility : Users reference potential improvements in multiple areas of well-being: digestion, mobility, post-workout soreness, and overall resilience
ALLERGY WARNING This product is contraindicated in an individual with a history of hypersensitivity to any of its ingredients
Inducible Nitric Oxide Synthase Inhibitors Abolished Histological protection by Lateischemic Preconditioning in Rat Retina
What the Data Actually Show | Evidence Level | Sermorelin Alone | GHK-Cu Alone | Sermorelin + GHK-Cu | |---|---|---|---| | Phase III RCT | Yes (pediatric GHD) | No | No | | Phase II RCT (adults) | Yes (Vittone 1997) | One skin-aging trial | No | | Animal studies | Multiple | Multiple | None identified | | In vitro mechanistic | Extensive | Extensive | None identified | | Case series / observational | Limited | Limited | Anecdotal only | The FDA-approved indication for sermorelin covers pediatric GH deficiency
US$ 24.01
US$ 29.37
US$ 29.49
